SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Henry Niman who wrote (18309)3/31/1998 11:44:00 AM
From: Arthur Radley  Respond to of 32384
 
OFF TOPIC:::::
Henry and other Scientist on the Thread:
I would appreciate your analysis of the news release that VION Pharmaceuticals issued at the oncology conference in New Orleans yesterday. Their TAPET(tm) technology and the use of salmonella in the treatment of cancer is certainly a novel approach to cancer treatments.



To: Henry Niman who wrote (18309)3/31/1998 11:49:00 AM
From: WTDEC  Respond to of 32384
 
Henry, LGNDW volume is almost twice LGND volume as of a few minutes ago. Very unusual.

W



To: Henry Niman who wrote (18309)3/31/1998 12:23:00 PM
From: dwc  Read Replies (2) | Respond to of 32384
 
It should be duly noted that this is the final day of March. We still have about 4 hours for all that madness. 8~)



To: Henry Niman who wrote (18309)3/31/1998 12:33:00 PM
From: AJAG  Read Replies (1) | Respond to of 32384
 
Hey Henry! The biotech rally is now underway, fueled by great
product news from Neurex (NXCO), Scios (SCIO) and Centocor
(CNTO)- so how come Ligand is not moving up? By the way, I am a new investor in NXCO. It looks like they have a big winner for
severe pain treatment. The phase 3 trial was terminated early
(today's news). It is my experience that this is the most explosive
positive news that you can get from a biotech company.